PMID- 31625415
OWN - NLM
STAT- MEDLINE
DCOM- 20200410
LR  - 20200410
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 15
IP  - 35
DP  - 2019 Dec
TI  - Lenalidomide maintenance post-transplantation in newly diagnosed multiple 
      myeloma: real-world outcomes and costs.
PG  - 4045-4056
LID - 10.2217/fon-2019-0422 [doi]
AB  - Aim: To compare real-world outcomes and costs among patients with newly diagnosed 
      multiple myeloma receiving lenalidomide-only maintenance (Len-Mt) versus no 
      maintenance after autologous hematopoietic stem cell transplantation. Patients & 
      methods: Time to next treatment (TTNT) was evaluated; costs were calculated for 
      0-12, 12-24 and 24-36 months postindex date. Results: Len-Mt cohort had longer 
      TTNT (HR: 0.43; p < 0.0001). Per-patient per-month costs during months 0-12 were 
      higher among patients, receiving Len-Mt (USD 13,095 vs USD 8910; p < 0.0001), due 
      to higher pharmacy costs - outpatient costs were lower. During months 12-24 and 
      24-36, outpatient costs were similar in both cohorts; total and pharmacy costs 
      remained elevated for patients receiving Len-Mt. Conclusion: Len-Mt improved 
      TTNT, initially reduced outpatient costs, but resulted in higher overall and 
      pharmacy costs.
FAU - Hari, Parameswaran
AU  - Hari P
AD  - Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 
      53226, USA.
FAU - Ung, Brian
AU  - Ung B
AD  - Celgene Corporation, Summit, NJ 07901, USA.
FAU - Abouzaid, Safiya
AU  - Abouzaid S
AD  - Celgene Corporation, Summit, NJ 07901, USA.
FAU - Agarwal, Amit
AU  - Agarwal A
AD  - Celgene Corporation, Summit, NJ 07901, USA.
FAU - Parikh, Kejal
AU  - Parikh K
AD  - Celgene Corporation, Summit, NJ 07901, USA.
LA  - eng
PT  - Journal Article
DEP - 20191018
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Antineoplastic Agents)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Costs and Cost Analysis
MH  - Female
MH  - Health Care Costs
MH  - Hematopoietic Stem Cell Transplantation/adverse effects/methods
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lenalidomide/administration & dosage/adverse effects/*therapeutic use
MH  - Maintenance Chemotherapy/economics/methods
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/diagnosis/*drug therapy/mortality
MH  - Postoperative Care
MH  - Retreatment
MH  - Retrospective Studies
MH  - Transplantation, Autologous
MH  - Treatment Outcome
OTO - NOTNLM
OT  - ASCT
OT  - autologous hematopoietic stem cell transplantation
OT  - healthcare resource utilization
OT  - lenalidomide
OT  - maintenance therapy
OT  - multiple myeloma
OT  - real world
EDAT- 2019/10/19 06:00
MHDA- 2020/04/11 06:00
CRDT- 2019/10/19 06:00
PHST- 2019/10/19 06:00 [pubmed]
PHST- 2020/04/11 06:00 [medline]
PHST- 2019/10/19 06:00 [entrez]
AID - 10.2217/fon-2019-0422 [doi]
PST - ppublish
SO  - Future Oncol. 2019 Dec;15(35):4045-4056. doi: 10.2217/fon-2019-0422. Epub 2019 
      Oct 18.